About
Bioinformatician.
Data Scientist.
Founder.
I haven't just analyzed precision medicine scientifically — I've built it, scaled it, and reimagined it under real-world conditions.
3
Foundings
A path between science and implementation
My goal is not to impress people with data.
My goal is to enable them to make better decisions.
I studied bioinformatics in Regensburg and earned my PhD at the Institute of Pharmacy at the University of Würzburg. My doctoral thesis focused on 4D-QSAR models — methods for predicting biological activity from molecular structure data.
At Novartis and Roche Diagnostics, I learned how data is used in the pharmaceutical industry and lab diagnostics — and where it fails. This shaped my thinking: not more data, but better questions.
With BioVariance, I experienced what it means not just to think about precision medicine, but to build it under real market conditions: research, laboratory operations, COVID scaling, EU projects like REVERT, BEATsep, and P4D.
ich.center and longcovid.expert are the consistent evolution of this experience.
Experience from implementation
What I learned from BioVariance.
Data alone creates no value.
Only interpretation, prioritization, and implementation turn high-quality measurements into a viable decision.
Science is only part of the system.
Health innovation needs equally good system design, robust processes, right timing, and a clear market logic.
Single tests are not enough.
That's why I develop decision and prevention systems today that connect measurement, context, and action.
The new chapter
The blind spot of precision medicine.
In 20 years working with molecular data, I realized: we capture more and more — genes, proteins, microbiome, metabolome. But we overlook something fundamental: the entrance. The channel through which the environment speaks to the body. The senses.
The Senses Code is the consistent evolution: multi-omics without sense-omics is incomplete. Health emerges not only from what we measure — but from what we perceive.
Milestones
A selection of the most formative stations.
Present
Founder & Strategic Advisor
ich.center · longcovid.expert
Personal longevity OS for individuals, specialized genetic orientation report for Long COVID/ME/CFS.
2022–2023
Harvard Medical School
Global Healthcare Leaders Program
Leadership and strategic thinking in the global healthcare system — perspective on systemic change, innovation diffusion, and digital transformation.
2013–2025
Founder & CEO BioVariance GmbH
Waldsassen / Tirschenreuth
AI-driven precision medicine and laboratory analytics. COVID-PCR lab, EU projects REVERT/BEATsep/P4D. TOP 100 Innovator.
Industry
Novartis & Roche Diagnostics
Cambridge / Basel
Industry, diagnostics, and translation. Data needs clinical and economic context.
PhD
Dr. rer. nat.
Julius Maximilian University of Würzburg
Institute of Pharmacy. 4D-QSAR models for predicting biological activity from molecular structure data.
Studies
Bioinformatics
University of Regensburg
Undergraduate studies in bioinformatics.
Scientific Resonance
Cited across disciplinary boundaries.
Pharmacology
Top 0.01%
Bioinformatics
Top 0.01%
Medicine
Top 0.13%
Data Mining
Top 0.04%
Artificial Intelligence
Top 0.2%
Impactio: "Top 5 Highly Cited Academic Fields" — as of March 1, 2023. Platform-based bibliometric assessment.
Let's get to know each other.
Whether strategy call, keynote, or collaboration — I look forward to the exchange.
No spam. Just a personal note when something new appears.